Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00627120 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects
A Phase 1 study, sponsored by VGX Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00627120: Completed Phase 1 study, sponsored by VGX Pharmaceuticals.
NCT00627120 is a Phase 1 study that has completed, run by VGX Pharmaceuticals. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00627120, a Phase 1 study, has completed, sponsored by VGX Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of a single dose of VGX-1027 in the range of 1-800mg.
Interventions
- DRUG VGX-1027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00627120
The ClinicalTrials.gov registry entry for NCT00627120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VGX Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VGX-1027 is the first listed.
NCT00627120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00627120 about?
NCT00627120 is a clinical study titled "Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects". To assess the safety and tolerability of a single dose of VGX-1027 in the range of 1-800mg.
What is the current status of trial NCT00627120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-02.
What interventions are being tested in trial NCT00627120?
The interventions under investigation include: VGX-1027 (DRUG).
Who is sponsoring clinical trial NCT00627120?
This trial is sponsored by VGX Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.